Search Results
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 08:00 ET Powering Growth: Kinderhook Fuels Next Chapter for Advanced Digital Cable
Advanced Digital Cable Inc. ("ADC" or the "Company"). Headquartered in Hayesville, Georgia, ADC is a manufacturer of wire and cable solutions, with a focus on low-voltage copper wire. ADC represents Kinderhook's
More news about: Kinderhook Industries
Sep 22, 2025, 02:51 ET Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
cadonilimab (PD-1/CTLA-4 bispecific antibody), as well as potentially first -in-class candidates such as AK130 and AK146D1 (Trop2/Nectin4 bispecific ADC). Preclinical studies indicate that dual blockade of the PD-1/VEGF and TIGIT/TGF-β pathways has synergistic therapeutic potential. This combination
More news about: Akeso, Inc.
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
proprietary technology platforms, including LeadsBody™ platform (a CD3 T-cell engager platform), X-body™ platform (a 4-1BB engager platform), TOPiKinectics™ (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.
More news about: Leads Biolabs
Sep 19, 2025, 09:18 ET Precision Biologics to Unveil In Vitro and In Vivo Efficacy of New ADC against human ovarian cancer at AACR Special Conference
efficacy: The efficacy of the ADC PB-vcMMAE-5 was assessed in OV-90 subcutaneous xenograft model established in NOD-SCID mice. The ADC PB-vcMMAE-5 was administered intravenously at doses 1, 3, 6 or 9 mg/kg, once per week for five weeks.On day 31 from first ADC infusion, most alive mice
More news about: Precision Biologics
Sep 19, 2025, 08:00 ET Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA
More news about: Antengene Corporation Limited
Sep 18, 2025, 07:00 ET Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
activity observed, including confirmed partial response (PR) and tumor regressions, with this first-in-class T-cell agonist combined with Trop2-directed ADC.STARt-002 continues enrollment across leading North American breast cancer centers
More news about: Marengo Therapeutics
Sep 17, 2025, 02:15 ET New AI-native processor for edge applications offers 100x power and performance improvements over 32-bit MCUs
The GPX10 Pro also features an Arm® Cortex®-M4F CPU core for classic control functions. Integrated analog functionality includes an ultra-low power ADC, enhanced I2S logic, and interfaces for up to eight simultaneous analog and 20 digital sensors. Ambient Scientific provides the comprehensive
More news about: Ambient Scientific
Sep 16, 2025, 10:30 ET Lilly announces plans to build $5 billion manufacturing facility in Virginia
in U.S. capital expansion commitments since 2020. At this site, Lilly will also boost its domestic manufacturing of antibody-drug conjugates (ADCs). An ADC is a targeted therapy designed to deliver potent medicines directly to diseased cells. By combining the precision of monoclonal antibodies with the power
More news about: Eli Lilly and Company
Sep 16, 2025, 10:06 ET Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
/PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) protein on the cancer cell surface. The therapy, named
More news about: Children's Hospital of Philadelphia
Sep 16, 2025, 05:30 ET Network Security Market Up 8 Percent in 2Q 2025 as SSE and ADC Surge, According to Dell'Oro Group
8 percent year-over-year (Y/Y). The expansion was driven by double-digit gains in Security Service Edge (SSE) and Application Delivery Controllers (ADC), as enterprises adopted AI-aware application protection and platform consolidation strategies to streamline operations and enhance defenses. In contrast,
More news about: Dell'Oro Group
Sep 15, 2025, 03:00 ET Mycenax y SPERA PHARMA forjan una alianza estratégica
integral para conjugados anticuerpo-fármaco (ADC) y bioconjugados, que abarca la síntesis de enlazadores/cargas útiles, la producción de fármacos, la formulación y el llenado y acabado aséptico. La alianza busca acelerar la comercialización de ADC para las compañías biofarmacéuticas, ofreciendo
More news about: Mycenax Biotech Inc.
Sep 15, 2025, 03:00 ET Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services
strategic partnership with KriSan Biotech further expanded its next-generation ADC technology platform. Together, Mycenax and SPERA PHARMA offer an end-to-end development and manufacturing solution. This empowers global ADC developers with speed, flexibility, and technical excellence. About
More news about: Mycenax Biotech Inc.
Sep 15, 2025, 03:00 ET Mycenax und SPERA PHARMA schließen strategische Allianz zur Optimierung der Dienstleistungen im Bereich der Herstellung von ADC-Wirkstoffen und Arzneimitteln
Partnerschaft mit KriSan Biotech im Jahr 2022 wurde die ADC-Technologieplattform der nächsten Generation weiter ausgebaut. Gemeinsam bieten Mycenax und SPERA PHARMA eine End-to-End-Lösung für Entwicklung und Herstellung an. Dies ermöglicht globalen ADC-Entwicklern Schnelligkeit, Flexibilität und technische
More news about: Mycenax Biotech Inc.
Sep 14, 2025, 20:00 ET Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients' lives," said Zhaoyuan "Tony" Chen, Chief Executive Officer of Phrontline Biopharma. "The initiation
More news about: Phrontline Biopharma
Sep 12, 2025, 00:35 ET Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig
proprietary technology platforms, including LeadsBody™ platform (a CD3 T-cell engager platform), X-body™ platform (a 4-1BB engager platform), TOPiKinectics™ (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.
More news about: Leads Biolabs
Sep 10, 2025, 21:00 ET Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List
society. In the first half of 2025, HLX43, an innovative drug developed by Henlius, became the world's first PD-L1-targeting antibody-drug conjugate (ADC) to advance into Phase II clinical trial. It is undergoing clinical studies for solid tumors such as non-small cell lung cancer (NSCLC) and thymic carcinoma
More news about: Fosun
Sep 10, 2025, 17:31 ET TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
drivers, market barriers, and key ADC companies, including AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Astellas, Roche, Pfizer (Seagen), Takeda, Ambrx, Daiichi Sankyo, Merck, Eisai, Bristol-Myers Squibb, Sanofi, NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics,
More news about: DelveInsight Business Research, LLP
Sep 10, 2025, 15:41 ET Tagworks Pharmaceuticals inicia la tercera dosis del ensayo clínico de fase 1 de TGW101
TGW101 es un ADC de última generación, el primero en su clase, dirigido a TAG-72 con una carga útil MMAE, desarrollado con base en la química de enlace Click-to-Release, propiedad de Tagworks. TGW101 es el primer ADC bioortogonal activado in vivo mediante química
More news about: Tagworks Pharmaceuticals BV
Sep 10, 2025, 15:00 ET Tagworks Pharmaceuticals gibt den Beginn der dritten Dosierungsstufe in der laufenden klinischen Phase-1-Studie mit TGW101 zur Behandlung solider Tumoren bekannt
ADC der nächsten Generation und der erste seiner Klasse, der auf TAG-72 mit einer MMAE-Nutzlast abzielt und auf der Grundlage der proprietären Click-to-Release-Linker-Chemie von Tagworks entwickelt wurde. TGW101 ist der erste bioorthogonale, in vivo durch Click-Chemie aktivierte ADC, der eine
More news about: Tagworks Pharmaceuticals BV
Sep 10, 2025, 14:57 ET Tagworks Pharmaceuticals annonce le début du troisième niveau de dose de l'essai clinique de phase 1 en cours de TGW101 pour le traitement des tumeurs solides
anticorps-médicament conjugué (ADC) de nouvelle génération, premier de sa catégorie, ciblant TAG-72 avec une charge utile monométhylauristatine E, développé sur la base de la chimie de liaison Click-to-Release propriétaire de Tagworks ; TGW101 est le premier ADC bio-orthogonal, in
More news about: Tagworks Pharmaceuticals BV
Sep 09, 2025, 10:01 ET Next Generation Antibody Therapeutics Market Size will Hit $22.88 Billion by 2033, Fueled by Breakthroughs in Oncology and AI-Driven Drug Design | DataM Intelligence
hematologic malignancies, and its ADC collaborations are progressing toward late-stage trials. Amgen's innovation is reinforced by AI-enabled discovery platforms, accelerating the identification of novel antibody targets. Recent FDA submissions for its oncology ADC candidates highlight Amgen's aggressive
More news about: DataM Intelligence 4 Market Research LLP
Sep 09, 2025, 09:00 ET Homecare Homebase Named 2025 McKnights Excellence in Technology Award Finalist
challenges that arose after the agency reduced its operations. Utilizing HCHB's Smart Scheduling tool resulted in a referral uptick and 15% monthly ADC increase for VNASEMO. In conjunction with implementing HCHB's Smart Scheduling tool, VNASEMO also adopted HCHB's Patient Visit Reminder tool in
More news about: Homecare Homebase
Sep 09, 2025, 07:00 ET Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activityExpect
More news about: Tagworks Pharmaceuticals BV
Sep 09, 2025, 07:00 ET Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activityExpect
More news about: Tagworks Pharmaceuticals BV